Anti-obesity Pharmacotherapy and Inflammation

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Inclusion Criteria:50% women (12) and 50% men (12)Race: 50% African American (6 women, 6 men), 50% White American (6 women, 6 men)Body mass index (BMI): over 30 kg/m2Exclusion Criteria:Taking medications with anti-inflammatory properties like glucocorticoids, prednisone, or non-steroidal anti-inflammatory medications, such as aspirin or Motrin Subjects on medications for long-term weight management such as phentermine-topiramate (Qsymia), orlistat (Xenical), naltrexone-bupropion (Contrave), and the glucagon-like peptide-1 receptor agonists such as liraglutide (Saxenda), and semaglutide (Wegovy).Prior history of cancerHaving any clinical symptoms of systemic inflammation, acute infections such as Coronavirus disease 2019, or chronic diseases such as cancer, tuberculosis, autoimmune disease, and AIDSAn adult unable to consentPrisonerPregnancy or breastfeeding women